TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, Naka et al. demonstrated the therapeutic efficacy of EW-7197, an orally bioavailable TGFβ signaling inhibitor, combined with tyrosine kynase inhibitors, in eliminating chronic myeloid leukemia initiating cells in vivo: the combination significantly delayed disease relapse and prolonged survival [142].